Evaluation of Artificial Intelligence System Based on Retinal Imaging in the Diagnosis and Treatment of Metabolic Dysfunction–Associated Steatotic Liver Disease and Fibrosis

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2600123310

Enrollment

Unknown

Registered

2026-04-23

Start date

2026-04-30

Completion date

Unknown

Last updated

2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

metabolic dysfunction steatotic liver disease

Interventions

AI system assists physician decision-making group:None

Biomarker assists physician decision-making group:None

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18 to 75 years. 2. Diagnosed with type 2 diabetes mellitus or metabolic syndrome. 3. Able to comply with and complete study-related examinations.

Exclusion criteria

Exclusion criteria: 1. Severe liver or kidney dysfunction. 2. Acute viral hepatitis. 3. Unable to undergo retinal fundus photography.

Design outcomes

Primary

Measure	Time frame
Unnecessary referral rate;	—

Secondary

Measure	Time frame
Biopsy-confirmed true positive cases;Avoided referral rate;Referral recommendation score;	—

Countries

China

Contacts

Public ContactChen Tingli

Shanghai Health and Medical Center

chentingli1028@163.com+86 185 6165 3019

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 1, 2026